# CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

> **NCT04734873** · PHASE3 · TERMINATED · sponsor: **Corvus Pharmaceuticals, Inc.** · enrollment: 46 (actual)

## Conditions studied

- Covid-19

## Interventions

- **DRUG:** CPI-006 2 mg/kg + SOC
- **DRUG:** CPI-006 1 mg/kg + SOC
- **DRUG:** Placebo + SOC

## Key facts

- **NCT ID:** NCT04734873
- **Lead sponsor:** Corvus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-25
- **Primary completion:** 2021-08-18
- **Final completion:** 2021-08-18
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Sponsor decision. Not related to safety issues.
- **Last updated:** 2022-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04734873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04734873, "CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04734873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*